This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Knight, J. B.
Right arrow Articles by Lee, S. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Knight, J. B.
Right arrow Articles by Lee, S. F.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, June 2008, p. 925-931, Vol. 15, No. 6
1071-412X/08/$08.00+0     doi:10.1128/CVI.00500-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Expression of a Functional Single-Chain Variable-Fragment Antibody against Complement Receptor 1 in Streptococcus gordonii{triangledown}

Jennifer B. Knight,1 Scott A. Halperin,1,3 Kenneth A. West,1 and Song F. Lee1,2,3*

Department of Microbiology and Immunology, Faculty of Medicine,1 Department of Applied Oral Sciences, Faculty of Dentistry, Dalhousie University,2 Department of Pediatrics, Dalhousie University, and the IWK Health Centre, Halifax, Nova Scotia, Canada3

Received 17 December 2007/ Returned for modification 21 January 2008/ Accepted 24 March 2008

Streptococcus gordonii, an oral commensal organism, is a candidate vector for oral-vaccine development. Previous studies have shown that recombinant S. gordonii expressing heterologous antigens was weakly immunogenic when delivered intranasally. In this study, antigen was specifically targeted to antigen-presenting cells (APC) in order to potentiate antigen-APC interactions and increase the humoral immune response to the antigen. To achieve this goal, a single-chain variable-fragment (scFv) antibody against complement receptor 1 (CR1) was constructed. Anti-CR1 scFv purified from Escherichia coli was able to bind to mouse mixed lymphocytes and bone marrow-derived dendritic cells. The in vivo function of the anti-CR1 scFv protein was assessed by immunizing mice intranasally with soluble scFv and determining the immune response against the hemagglutinin (HA) peptide located on the carboxy terminus of the scFv. The serum anti-HA immunoglobulin G (IgG) immune response was dose dependent; as little as 100 ng of anti-CR1 scFv induced a significant IgG immune response, while such a response was minimal when the animals were given an unrelated scFv. The anti-CR1 scFv was expressed in S. gordonii as a secreted protein, which was functional, as it bound to dendritic cells. Mice orally colonized by the anti-CR1-secreting S. gordonii produced an anti-HA IgG immune response, indicating that such an approach can be used to increase the immune response to antigens produced by this bacterium.

* Corresponding author. Mailing address: Department of Applied Oral Sciences, Faculty of Dentistry, Dalhousie University, Halifax, Nova Scotia, Canada B3H 3J5. Phone: (902) 470-7522/494-8799. Fax: (902) 494-6621. E-mail: Song.Lee{at}Dal.Ca

{triangledown} Published ahead of print on 2 April 2008.

Clinical and Vaccine Immunology, June 2008, p. 925-931, Vol. 15, No. 6
1071-412X/08/$08.00+0     doi:10.1128/CVI.00500-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»